Default company panoramic image
Logo

BetaStem Therapeutics Inc

Our fundamental vision is to cure diabetic retinopathy by regenerating damaged blood vessels in a patient's eye using autologous stem cells.

  • Stage Product In Development
  • Industry Biotechnology
  • Location San Francisco, CA, USA
  • Currency USD
  • Founded June 2006
  • Employees 4
  • Website betastemtherapy.com

Company Summary

BetaStem Therapeutics Inc. is commercializing an innovative approach to cure diabetic retinopathy by repairing and regenerating damaged blood vessels in a patient’s eye. The treatment is based on extracting stem cells from a patient’s own blood and “activating” them through treatment with phosphorodiamidate morphlino oligomers (PMO).

Team

  • Default avatar
    Stephen Barlelmez
    Dr.

    Dr. Bartelmez is a leading researcher in stem cells and antisense technologies. He has served as President and Founder of BetaStem Therapeutics Inc. since the inception of the Company in 2006. Previously, he held the position of President and CEO, Ixion Biotechnology Inc. from 2005 to 2006. He also served as the Vice President and Director of Research, HemoGenix Inc. from 2004 to 2005 and Director of Research at ViaCell Singapore (subsidiary of V

  • Default avatar
    Charles Garcia
    Dr.

    Dr. Garcia is an internationally known researcher and clinician has a lifelong goal of finding a cure for retinitis pigmentosa. His clinical practice focuses on diagnosis and treatment of various vitreoretinal diseases. His primary surgical interests include retinal detachment, proliferative vitreo-retinopathy, and diabetic retinopathy. He has special interest in innovative therapies for macular degeneration and inherited retinal diseases. He als

  • Default avatar
    Robert Martinsons
    Mr.

    Robert Martinsons, VP Marketing & Business Development is an accomplished high-tech executive with more than 30 years of both large company and small business unit experience in the medical device/instrumentation and electronics industries. He has consulted for numerous biomedical companies in technology commercialization and business development. Robert developed two new business units at a Fortune 100 firm that grew to combined revenues in exce

  • Default avatar
    Leland Johnson
    Mr.

    Leland is an entrepreneur in biotechnology with 15 years of experience working for small biotechnology companies and large public and private pharmaceutical companies. Over the past several years, Leland has focused on business development by connecting customers to service experts in the area of pre-clinical and technology development. Through The Conditas Group, Leland has established professional agreements with more than fifteen small-niche C

Advisors

  • Default avatar
    Frederick J. Dorey, Cooley LLP
    Lawyer
    Unconfirmed

Previous Investors

  • Default avatar
    National Institutes of Health
    Unconfirmed
    Default avatar
    Dr. Stephen Bartelmez
    Unconfirmed